JD Supply Chain FinTech Empowers Pharmaceutical Sector, Injecting Over RMB 130 Million into Jiuzhou Tong's Downstream Network

Currently, the pharmaceutical industry is undergoing profound transformation, and building an efficient, collaborative, and innovative pharmaceutical supply chain ecosystem has become the key for enterprises to break through. Recently, at the 2024 JD Supply Chain Fintech Trade in Services Industry Conference, Zhang Huatao, Deputy General Manager of the Distribution Business Division of Jointown Pharmaceutical Group, shared successful case studies of the collaboration between Jointown and JD Technology, showcasing the deep cooperation and win-win outcomes achieved by both parties in the pharmaceutical supply chain sector, thereby providing new pathways for industry development.

Jointown Pharmaceutical Group, a leading technology-driven integrated service provider for the full-chain pharmaceutical industry in China, boasts a development history of nearly 40 years. The company’s core business spans pharmaceutical distribution, pharmaceutical CSO (Contract Sales Organization), pharmaceutical manufacturing, and new retail pharmacy, establishing a scarce supply chain service platform with a scale of hundreds of billions of yuan and achieving comprehensive procurement across all categories, omni-channel coverage, and full-scenario service layout.

Amid increasingly fierce market competition and evolving customer demands in the pharmaceutical industry, Jointown Pharmaceutical Group has consistently maintained keen market insights and actively explored innovative cooperation models. Its partnership with JD Technology represents a significant strategic move by Jointown in the field of supply chain finance. More than a decade ago, when JD was initially laying out its pharmaceutical sector, it established contact with Jointown.

According to reports, the collaboration between the two parties can be divided into four phases: In December 2023, a strategic cooperation agreement was signed, ushering in a new chapter of partnership; in April 2024, the first offline customer contract was finalized, marking the entry into a phase of substantive implementation; in June 2024, monthly loan disbursements reached RMB 60 million, achieving a significant breakthrough; and by November 2024, the total loan disbursement amount in the first year had exceeded RMB 130 million, covering 11 provinces including Guangdong, Shaanxi, and Henan, demonstrating remarkable collaborative achievements.

To address the working capital challenges faced by Jointown Pharmaceutical Group’s downstream clients, JD Supply Chain Fintech provides procurement financing solutions. Zhang Huatao revealed that during the mid-2026 collection campaign, this product demonstrated significant advantages, with a maximum single-disbursement limit of RMB 5 million and preferential interest rates ranging from 3% to 6%. Thanks to its streamlined application requirements and efficient approval process, Jointown facilitated loans for 33 clients in June alone, with cumulative disbursements reaching RMB 60 million. Notably, a chain pharmacy based in Shaanxi Province secured a cumulative credit line of RMB 9 million.

Furthermore, the two parties have established a rapid response mechanism. The JD Technology team, with its professional, efficient, and pragmatic work ethic, has accelerated response times from T+1 to T+0, thereby promptly meeting customers’ funding needs. Tailoring customer acquisition strategies to different client segments, the partners have also introduced incentives such as interest-free coupons and credit limit increases, driving deeper collaboration.

Zhang Huatao stated, “The collaboration with JD Technology marks a significant milestone in the development history of Jointown Pharmaceutical Group. We are deeply impressed by their execution capabilities, team vitality, and innovative prowess. This partnership has not only provided us with tangible financial support but also introduced new perspectives and models for the development of the entire pharmaceutical supply chain.”

Looking ahead, the partnership between the two parties holds broad prospects. Zhang Huatao stated that in 2025, Jointown Pharmaceutical Group plans to acquire 100 new clients, focusing on tapping into high-potential customers and supporting their development through joint visits, training, and empowerment initiatives. The company’s regional coverage will expand from 11 to 16 areas. Furthermore, cooperation on projects such as JD Pay and JD Baitiao is progressing steadily, which will further enhance the service quality and efficiency of the pharmaceutical supply chain.